Removing 340B Pass-Through Would be Detrimental to US Healthcare Savings

WASHINGTON, D.C. (February 26, 2019) — The Biosimilars Forum released the following statement in response to written testimony submitted by Johnson & Johnson for today’s Senate Finance Committee hearing, titled “Drug Pricing in America: A Prescription for Change, Part II,” which suggests removal of the 340B pass-through:

The 340B pass-through rule for biosimilars is one of the few tools available to help create a level playing field and cost savings for disproportionate hospitals in the U.S. More policies like this need to be maintained to advance and support uptake of biosimilars and cost savings for patients the US. Any attempt to roll back or remove the 340B pass-through is at the detriment to biosimilars, which are one of the most common sense options to saving the U.S. healthcare system 54 billion over ten years.